Redhill Biopharma Ltd (RDHL)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $3.33M
Last updated: Nov 17, 2026 at 11:02 AM ET
Redhill Biopharma Ltd (RDHL) Financials: Revenue, Profit and Cash Flow
Redhill Biopharma reported revenue of $286.00K for the fiscal year ended Dec 31, 2025, down 96.4% from the year before. That year, net income was -$429.00K with a net margin of -150.0%, operating cash flow was -$9.65M and free cash flow was -$9.66M. The quarter ended Jun 30, 2026 had net income of -$6.10M.
Revenue and Margins
Over the 9 years to Dec 2025, revenue grew from $101.00K, a compound annual rate of 12.3%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $286.00K | -96.4% | 100.0% | -2765.4% | -150.0% |
| Dec 2024 | $8.04M | +23.2% | 60.3% | -181.7% | -102.8% |
| Dec 2023 | $6.53M | -89.4% | 47.0% | 193.4% | 366.2% |
| Dec 2022 | $61.80M | -27.9% | 46.1% | -69.3% | -116.0% |
| Dec 2021 | $85.76M | +33.2% | 42.4% | -94.6% | -114.0% |
| Dec 2020 | $64.36M | +923.0% | 42.7% | -99.0% | -118.4% |
| Dec 2019 | $6.29M | -24.7% | 64.1% | -686.7% | -672.5% |
| Dec 2018 | $8.36M | +108.6% | 66.1% | -470.5% | -464.4% |
| Dec 2017 | $4.01M | +3867.3% | 46.9% | -1297.0% | -1136.6% |
| Dec 2016 | $101.00K | N/A | -30140.6% | -30240.6% | -29079.2% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $286.00K | $8.04M | $6.53M | $61.80M | $85.76M | $64.36M | $6.29M | $8.36M | $4.01M | $101.00K |
| Cost of revenue | N/A | $3.19M | $3.46M | $33.34M | $49.41M | $36.89M | $2.26M | $2.84M | $2.13M | $30.54M |
| Gross profit | $286.00K | $4.85M | $3.07M | $28.46M | $36.35M | $27.47M | $4.03M | $5.52M | $1.88M | -$30.44M |
| Research and development | $2.02M | $1.59M | $3.53M | $7.28M | $29.50M | $16.49M | $17.42M | $24.86M | $32.97M | $25.24M |
| Operating income | -$7.91M | -$14.61M | $12.63M | -$42.84M | -$81.14M | -$63.68M | -$43.20M | -$39.33M | -$51.97M | -$30.54M |
| Net income | -$429.00K | -$8.27M | $23.92M | -$71.67M | -$97.74M | -$76.17M | -$42.30M | -$38.82M | -$45.54M | -$29.37M |
| EBITDA | -$7.65M | -$7.59M | $26.27M | -$22.18M | -$63.03M | -$54.98M | -$40.70M | -$38.73M | -$45.46M | -$30.50M |
Quarterly
| Line item | Jun 2026 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $2.04M | $2.04M | $2.74M | $2.74M | $1.29M | $1.29M | $567.50K | $567.50K | $1.80M | $12.80M | $12.80M |
| Gross profit | N/A | $1.24M | $1.24M | $1.84M | $1.84M | $584.00K | $584.00K | $47.00K | $47.00K | $990.00K | $4.20M | $4.20M |
| Operating income | -$4.13M | -$2.19M | -$2.19M | -$3.08M | -$3.08M | -$4.22M | -$4.22M | -$6.02M | -$6.02M | -$4.41M | -$9.95M | -$9.95M |
| Net income | -$6.10M | -$2.07M | -$2.07M | -$2.59M | -$2.59M | -$1.54M | -$1.54M | -$13.54M | -$13.54M | $761.00K | -$3.73M | $2.49M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $170.00K by $3.80M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $25.34M | $18.04M | $23.05M | $158.87M | $181.19M | $180.24M | $74.10M | $62.41M | $57.34M | $74.21M |
| Current assets | $6.53M | $11.91M | $16.14M | $85.90M | $89.15M | $70.50M | $53.21M | $56.79M | $51.68M | $67.81M |
| Cash and equivalents | $3.97M | $4.62M | $5.57M | $19.97M | $29.47M | $29.30M | $29.02M | $29.00M | $16.45M | $53.79M |
| Total liabilities | $21.08M | $22.73M | $20.98M | $207.27M | $172.31M | $166.38M | $14.10M | $11.22M | $12.28M | $11.51M |
| Short-term debt | $170.00K | $353.00K | $718.00K | $116.25M | $1.62M | $1.71M | $834.00K | N/A | N/A | N/A |
| Long-term debt | N/A | N/A | N/A | N/A | $83.62M | $81.39M | N/A | N/A | $448.00K | $6.16M |
| Shareholder equity | $4.27M | -$4.68M | $2.07M | -$48.40M | $8.88M | $13.86M | $60.00M | $51.19M | $45.06M | $62.70M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $26.27M | $25.34M | $25.34M | $25.34M | $18.38M | $18.38M | $18.04M | $18.04M | $22.02M | $22.02M | $23.05M | $23.05M |
| Total liabilities | $27.35M | $21.08M | $21.08M | $21.08M | $22.79M | $22.79M | $22.73M | $22.73M | $21.96M | $21.96M | $20.98M | $20.98M |
| Cash and equivalents | $5.16M | $3.97M | $3.97M | $1.35M | $2.87M | $2.87M | $4.62M | $1.88M | $7.28M | $7.28M | $5.57M | $5.57M |
| Shareholder equity | -$1.08M | $4.27M | $4.27M | $4.27M | -$4.41M | -$4.41M | -$4.68M | -$4.68M | $61.00K | $61.00K | $2.07M | $2.07M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.65M | -$9.37M | -$35.82M | -$29.18M | -$65.05M | -$48.58M | -$40.75M | -$34.46M | -$44.77M | -$28.26M |
| Capital expenditures | $5.00K | $9.00K | $11.00K | $198.00K | $115.00K | $53.77M | $203.00K | $58.00K | $1.18M | $120.00K |
| Free cash flow | -$9.66M | -$9.38M | -$35.83M | -$29.38M | -$65.16M | -$102.35M | -$40.95M | -$34.52M | -$45.95M | -$28.38M |
| Investing cash flow | $1.69M | -$9.00K | $3.99K | $8.30M | -$8.14M | -$35.65M | $5.16M | $5.35M | -$18.58M | $24.47M |
| Financing cash flow | $7.32M | $8.42M | $21.38M | $11.45M | $73.46M | $84.37M | $35.51M | $41.76M | $25.65M | $36.02M |
Quarterly
| Line item | Jun 2026 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.56M | -$2.51M | -$2.51M | -$1.59M | -$1.59M | -$3.09M | -$3.09M | N/A | -$9.02M | -$10.59M | -$2.42M | -$2.42M |
| Capital expenditures | $14.00K | $2.00K | $2.00K | $4.00K | $4.00K | $500 | $500 | $0 | $2.00K | $7.00K | N/A | $0 |
| Free cash flow | -$4.58M | -$2.51M | -$2.51M | -$1.60M | -$1.60M | -$3.09M | -$3.09M | N/A | -$9.02M | -$10.60M | N/A | -$2.42M |
Frequently Asked Questions About RDHL
What is Redhill Biopharma's annual revenue?
Redhill Biopharma reported revenue of $286.00K for the fiscal year ended Dec 31, 2025.
How fast is Redhill Biopharma's revenue growing?
Revenue was down 96.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -83.3%.
Is Redhill Biopharma profitable?
No. Redhill Biopharma reported net income of -$429.00K for the fiscal year ended Dec 31, 2025, with a net margin of -150.0%.
How much free cash flow does RDHL generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$9.65M minus capital expenditures of $5.00K produced free cash flow of -$9.66M.
How much debt does Redhill Biopharma have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $170.00K and cash and equivalents of $3.97M.
RDHL pages: Overview, Financials, Government Contracts